Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer

T. Y. Chao, W. S. Hwang, M. J. Yang, J. Y. Chang, C. C. Wang, E. J. Hseuh, S. H. Huang, W. C. Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. Non-small cell lung cancer (NSCLC) has a relatively low response rate to systemic chemotherapy. Recently, several investigations have shown that interferon may augment the cytotoxic effect of chemotherapeutic agents and may improve the result of chemotherapy in treating cancers. Methods. An open-label noncomparative phase II study investigated the efficacy and safety of combined chemoimmunotherapy for NSCLC using IFN-alpha, given by intramuscular injection with 9 million units thrice a week for a maximum of 26 weeks, and cisplatin by intravenous infusion, 100 mg/m2, every 4 weeks for a maximum of 6 cycles. Ten patients, with histology-confirmed NSCLC at stage IV of their diseases were enrolled. They included 5 men and 5 women, with an average age of 53.7 year. Five of them had adenocarcinoma; the other five had squamous cell carcinoma. Results. Five patients, including two patients with squamous cell carcinoma and three with adenocarcinoma, obtained a partial response (response rate 50%). The time needed to achieve a sustained response ranged from 5 to 13 weeks with a median of 8 weeks. The response duration ranged from 14 to 37 weeks with a median of 20 weeks. The overall survival time for the ten patients ranged from 2 to 20 months with a median of 8 months. All 10 patients needed dose modifications of IFN-alpha and/or cisplatin because of myelosuppression and/or impaired renal function. Other frequently encountered side effects included gastrointestinal disturbances and a flu-like syndrome, but these were well tolerated. Conclusions. These preliminary results indicate that chemoimmunotherapy with IFN-alpha and cisplatin can be an effective alternative therapy for patients with advanced NSCLC, but there are significant side effects.

Original languageEnglish
Pages (from-to)232-238
Number of pages7
JournalChinese Medical Journal (Taipei)
Volume56
Issue number4
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Interferon-alpha
Non-Small Cell Lung Carcinoma
Cisplatin
Squamous Cell Carcinoma
Adenocarcinoma
Drug Therapy
Intramuscular Injections
Complementary Therapies
Intravenous Infusions
Interferons
Histology
Kidney
Safety
Survival
Neoplasms

Keywords

  • chemoimmunotherapy
  • cisplatin
  • interferon-alpha
  • non-small cell lung cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chao, T. Y., Hwang, W. S., Yang, M. J., Chang, J. Y., Wang, C. C., Hseuh, E. J., ... Chen, W. C. (1995). Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer. Chinese Medical Journal (Taipei), 56(4), 232-238.

Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer. / Chao, T. Y.; Hwang, W. S.; Yang, M. J.; Chang, J. Y.; Wang, C. C.; Hseuh, E. J.; Huang, S. H.; Chen, W. C.

In: Chinese Medical Journal (Taipei), Vol. 56, No. 4, 1995, p. 232-238.

Research output: Contribution to journalArticle

Chao, TY, Hwang, WS, Yang, MJ, Chang, JY, Wang, CC, Hseuh, EJ, Huang, SH & Chen, WC 1995, 'Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer', Chinese Medical Journal (Taipei), vol. 56, no. 4, pp. 232-238.
Chao, T. Y. ; Hwang, W. S. ; Yang, M. J. ; Chang, J. Y. ; Wang, C. C. ; Hseuh, E. J. ; Huang, S. H. ; Chen, W. C. / Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer. In: Chinese Medical Journal (Taipei). 1995 ; Vol. 56, No. 4. pp. 232-238.
@article{45ddccf19f2d425e9527b4019b68b593,
title = "Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer",
abstract = "Background. Non-small cell lung cancer (NSCLC) has a relatively low response rate to systemic chemotherapy. Recently, several investigations have shown that interferon may augment the cytotoxic effect of chemotherapeutic agents and may improve the result of chemotherapy in treating cancers. Methods. An open-label noncomparative phase II study investigated the efficacy and safety of combined chemoimmunotherapy for NSCLC using IFN-alpha, given by intramuscular injection with 9 million units thrice a week for a maximum of 26 weeks, and cisplatin by intravenous infusion, 100 mg/m2, every 4 weeks for a maximum of 6 cycles. Ten patients, with histology-confirmed NSCLC at stage IV of their diseases were enrolled. They included 5 men and 5 women, with an average age of 53.7 year. Five of them had adenocarcinoma; the other five had squamous cell carcinoma. Results. Five patients, including two patients with squamous cell carcinoma and three with adenocarcinoma, obtained a partial response (response rate 50{\%}). The time needed to achieve a sustained response ranged from 5 to 13 weeks with a median of 8 weeks. The response duration ranged from 14 to 37 weeks with a median of 20 weeks. The overall survival time for the ten patients ranged from 2 to 20 months with a median of 8 months. All 10 patients needed dose modifications of IFN-alpha and/or cisplatin because of myelosuppression and/or impaired renal function. Other frequently encountered side effects included gastrointestinal disturbances and a flu-like syndrome, but these were well tolerated. Conclusions. These preliminary results indicate that chemoimmunotherapy with IFN-alpha and cisplatin can be an effective alternative therapy for patients with advanced NSCLC, but there are significant side effects.",
keywords = "chemoimmunotherapy, cisplatin, interferon-alpha, non-small cell lung cancer",
author = "Chao, {T. Y.} and Hwang, {W. S.} and Yang, {M. J.} and Chang, {J. Y.} and Wang, {C. C.} and Hseuh, {E. J.} and Huang, {S. H.} and Chen, {W. C.}",
year = "1995",
language = "English",
volume = "56",
pages = "232--238",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

TY - JOUR

T1 - Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer

AU - Chao, T. Y.

AU - Hwang, W. S.

AU - Yang, M. J.

AU - Chang, J. Y.

AU - Wang, C. C.

AU - Hseuh, E. J.

AU - Huang, S. H.

AU - Chen, W. C.

PY - 1995

Y1 - 1995

N2 - Background. Non-small cell lung cancer (NSCLC) has a relatively low response rate to systemic chemotherapy. Recently, several investigations have shown that interferon may augment the cytotoxic effect of chemotherapeutic agents and may improve the result of chemotherapy in treating cancers. Methods. An open-label noncomparative phase II study investigated the efficacy and safety of combined chemoimmunotherapy for NSCLC using IFN-alpha, given by intramuscular injection with 9 million units thrice a week for a maximum of 26 weeks, and cisplatin by intravenous infusion, 100 mg/m2, every 4 weeks for a maximum of 6 cycles. Ten patients, with histology-confirmed NSCLC at stage IV of their diseases were enrolled. They included 5 men and 5 women, with an average age of 53.7 year. Five of them had adenocarcinoma; the other five had squamous cell carcinoma. Results. Five patients, including two patients with squamous cell carcinoma and three with adenocarcinoma, obtained a partial response (response rate 50%). The time needed to achieve a sustained response ranged from 5 to 13 weeks with a median of 8 weeks. The response duration ranged from 14 to 37 weeks with a median of 20 weeks. The overall survival time for the ten patients ranged from 2 to 20 months with a median of 8 months. All 10 patients needed dose modifications of IFN-alpha and/or cisplatin because of myelosuppression and/or impaired renal function. Other frequently encountered side effects included gastrointestinal disturbances and a flu-like syndrome, but these were well tolerated. Conclusions. These preliminary results indicate that chemoimmunotherapy with IFN-alpha and cisplatin can be an effective alternative therapy for patients with advanced NSCLC, but there are significant side effects.

AB - Background. Non-small cell lung cancer (NSCLC) has a relatively low response rate to systemic chemotherapy. Recently, several investigations have shown that interferon may augment the cytotoxic effect of chemotherapeutic agents and may improve the result of chemotherapy in treating cancers. Methods. An open-label noncomparative phase II study investigated the efficacy and safety of combined chemoimmunotherapy for NSCLC using IFN-alpha, given by intramuscular injection with 9 million units thrice a week for a maximum of 26 weeks, and cisplatin by intravenous infusion, 100 mg/m2, every 4 weeks for a maximum of 6 cycles. Ten patients, with histology-confirmed NSCLC at stage IV of their diseases were enrolled. They included 5 men and 5 women, with an average age of 53.7 year. Five of them had adenocarcinoma; the other five had squamous cell carcinoma. Results. Five patients, including two patients with squamous cell carcinoma and three with adenocarcinoma, obtained a partial response (response rate 50%). The time needed to achieve a sustained response ranged from 5 to 13 weeks with a median of 8 weeks. The response duration ranged from 14 to 37 weeks with a median of 20 weeks. The overall survival time for the ten patients ranged from 2 to 20 months with a median of 8 months. All 10 patients needed dose modifications of IFN-alpha and/or cisplatin because of myelosuppression and/or impaired renal function. Other frequently encountered side effects included gastrointestinal disturbances and a flu-like syndrome, but these were well tolerated. Conclusions. These preliminary results indicate that chemoimmunotherapy with IFN-alpha and cisplatin can be an effective alternative therapy for patients with advanced NSCLC, but there are significant side effects.

KW - chemoimmunotherapy

KW - cisplatin

KW - interferon-alpha

KW - non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0028790650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028790650&partnerID=8YFLogxK

M3 - Article

C2 - 8548664

AN - SCOPUS:0028790650

VL - 56

SP - 232

EP - 238

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 4

ER -